05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Bridge, Daewoong partner on BBT-401 for ulcerative colitis

Bridge Biotherapeutics Inc. (Seongnam, South Korea) and Daewoong Pharmaceutical Co. Ltd. (KSE:069620) partnered to co-develop BBT-401 to treat ulcerative colitis. Bridge will receive an undisclosed upfront payment and be eligible for up to $40 million...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:16 , Nov 29, 2018 |  BC Innovations  |  Translation in Brief

Beyond BRCA

Researchers at the German Cancer Research Center have identified synthetic lethal markers beyond BRCA that expand the pool of patients who may benefit from PARP inhibitors and other compounds targeting DNA damage repair pathways. In...
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Bridge's ulcerative colitis candidate headed for Phase II

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said single and multiple ascending doses of oral ulcerative colitis candidate BBT-401 were well tolerated with minimal systemic exposure observed in a Phase I trial in 80 healthy volunteers....
15:54 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
16:25 , Nov 13, 2018 |  BioCentury  |  Finance

Kymera’s degradation toolbox

As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
12:03 , Nov 13, 2018 |  BC Extra  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
22:59 , Nov 1, 2018 |  BC Extra  |  Tools & Techniques

Selective degradation could be on horizon for imids

A Science study published Thursday suggests selective degradation of hard-to-drug zinc finger transcription factors could be achieved by modifying thalidomide or its analogs, collectively called imids. The results put forth a recipe to predict which...